# Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/final-overall-survival-results-from-a-randomised-phase-iii-study-of-erlotinib/

## Facts

| Field | Value |
| --- | --- |
| Author Names | C. Zhou,Yi‐Long Wu,G. Chen,J. Feng,Xuetong Liu,C. Wang,S. Zhang,J. Wang,Songwen Zhou,Shengxiang Ren,Shun Lü,L. Zhang,Chengping Hu,Chengping Hu,Yi Luo,Lin Chen,M. Ye,Juanjuan Huang,X. Zhi,Y. Zhang,Qingyu Xiu,W. F. Mader,L. Zhang,Changxuan You |
| Citations | 468 |
| DOI | 10.1093/annonc/mdv276 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2210071992 |
| PMID | 26141208 |
| Type | article |
| Year | 2015 |

## Paper authors

- [C. Zhou](https://scholariq.org/researchers/c-zhou/)
- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.